IMRX Stock Overview
A clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Immuneering Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.51 |
| 52 Week High | US$3.83 |
| 52 Week Low | US$1.00 |
| Beta | -0.26 |
| 1 Month Change | 2.03% |
| 3 Month Change | -35.47% |
| 1 Year Change | -35.74% |
| 3 Year Change | -79.68% |
| 5 Year Change | n/a |
| Change since IPO | -91.42% |
Recent News & Updates
Recent updates
Immuneering (NASDAQ:IMRX) Will Have To Spend Its Cash Wisely
Mar 18
Companies Like Immuneering (NASDAQ:IMRX) Could Be Quite Risky
Aug 30Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?
May 13Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone
Mar 19Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?
Jan 06We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate
Aug 17Immuneering wins FDA nod to study lead asset in solid tumors
Sep 30Immuneering seeks FDA nod to conduct clinical trial for lead cancer candidate
Sep 02Immuneering initiated a Buy by Chardan, PT set to $18
Jul 08Shareholder Returns
| IMRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.0% | -6.2% | -5.6% |
| 1Y | -35.7% | -10.4% | 3.3% |
Return vs Industry: IMRX underperformed the US Biotechs industry which returned -8.7% over the past year.
Return vs Market: IMRX underperformed the US Market which returned 8.4% over the past year.
Price Volatility
| IMRX volatility | |
|---|---|
| IMRX Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.4% |
Stable Share Price: IMRX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IMRX's weekly volatility has decreased from 16% to 9% over the past year.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 66 | Ben Zeskind | immuneering.com |
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Immuneering Corporation Fundamentals Summary
| IMRX fundamental statistics | |
|---|---|
| Market cap | US$55.98m |
| Earnings (TTM) | -US$61.04m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs IMRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$61.04m |
| Earnings | -US$61.04m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.70 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did IMRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/03 06:40 |
| End of Day Share Price | 2025/04/03 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Immuneering Corporation is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yevgeniya Livshits | Chardan Capital Markets, LLC |
| Michael Yee | Jefferies LLC |
| Graig Suvannavejh | Mizuho Securities USA LLC |